The analyst firm raised its price target for the medical devices company to $158 from $135.
BMO analysts raised their 2016 EPS estimates for the company to $4.65 a share from their previous estimates of $4.51 a share. The analyst firm also raised its 2017 EPS estimates for the company to $5.34 a share from its previous estimate of $5.12 a share.
"Since ACC, shares of EW have declined 11% versus the S&P 500 flat. We have a variety of theories on the reasons, and the stock has begun to recover," BMO analysts wrote. "Based on an analysis of relative P/E multiples, expense leverage, conversations with management, and our latest physician survey, we believe that shares of EW are positioned for another leg of ascent."
Separately, TheStreet Ratings team rates EDWARDS LIFESCIENCES CORP as a Buy with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation:
"We rate EDWARDS LIFESCIENCES CORP (EW) a BUY. This is driven by a number of strengths, which we believe should have a greater impact than any weaknesses, and should give investors a better performance opportunity than most stocks we cover. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity and solid stock price performance. We feel its strengths outweigh the fact that the company shows weak operating cash flow."